Compare MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MONDELEZ INTERNATIONAL INC Common Stock vs TransMedics Group Inc — how do they compare? MONDELEZ INTERNATIONAL INC Common Stock trades at $60.54 (market cap $77.43B), while TransMedics Group Inc trades at $78.2 (market cap $2.74B). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is far larger — about 28.3× TransMedics Group Inc's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays a 3.43% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold MONDELEZ INTERNATIONAL INC Common Stock for 107 Days and TransMedics Group Inc for 24 Days on average.
| MDLZ | TMDX | |
|---|---|---|
Market Cap | $77.43B | $2.74B |
Volume | 7,695,104 | 949,331 |
Sector | Consumer Staples | Health |
52-Week High | $64.99 | $150.42 |
52-Week Low | $51.51 | $61.99 |
Typical Hold Time | 107 Days | 24 Days |
Enterprise Value | $97.78B | $3.13B |
Dividend Yield | 3.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mondelez International (MDLZ) trades at $60.39, up 1.7% with a bullish technical signal and strong analyst support. The stock shows consistent earnings beats with Q2 2026 EPS of $0.73 exceeding expectations, supported by $38.54B revenue in 2025. Recent dividend increase to $0.52 per share and positive media coverage highlight management's confidence in cash flow stability. Valuation metrics include P/E of 22.22 and P/S of 1.97, trading below the consensus price target of $70.29.
MDLZ presents a compelling investment case with 76% analyst buy ratings and 16% upside to target, though cocoa cost pressures and margin compression from 13.76% in 2023 to 6.36% in 2025 pose near-term risks. The company's global brand portfolio and emerging market growth provide long-term stability, but investors should monitor commodity inflation's impact on profitability amid current neutral oscillator signals.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
